Browsing University of Galway Support Services by Subject "tyrosine kinase"
Now showing items 1-5 of 5
-
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase cml patients treated with imatinib mesylate
(American Society of Hematology, 2004-01-15)We followed 141 patients treated with imatinib mesylate (>300 mg) for chronic-phase chronic myelogenous leukemia (CML) following failure of treatment with interferon. During 12 months from the start of imatinib mesylate ... -
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
(New England Journal of Medicine (NEJM/MMS), 2015-12-17)BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, ... -
Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent manner
(Springer Nature, 2014-05-01)Nerve growth factor (NGF) is well characterised as an important pro-survival factor in neuronal cells that can inhibit apoptotic cell death upstream of mitochondrial outer membrane permeabilisation. Here we addressed the ... -
The impact of clonal evolution on response to imatinib mesylate (sti571) in accelerated phase cml
(American Society of Hematology, 2002-05-13) -
The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia
(American Association for Cancer Research (AACR), 2009-10-13)Pyrrolo-1,5-benzoxazepine-15 (PBOX-15) is a novel microtubule depolymerization agent that induces cell cycle arrest and subsequent apoptosis in a number of cancer cell lines. Chronic lymphocytic leukemia (CLL) is characterized ...